AU Patent

AU2022405079A1 — Combinations

Assigned to AN2 Therapeutics Inc · Expires 2024-06-27 · 2y expired

What this patent protects

This invention relates to, among other items, treating non-tuberculosis

USPTO Abstract

This invention relates to, among other items, treating non-tuberculosis

Drugs covered by this patent

amikacin-sulfate (AMIKACIN SULFATE)

Patent Metadata

Patent number: AU2022405079A1
Jurisdiction: AU
Classification: —
Expires: 2024-06-27
Drug substance claim: No
Drug product claim: No
Assignee: AN2 Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.